Mon, Oct 20, 2014, 8:08 AM EDT - U.S. Markets open in 1 hr 22 mins

Recent

% | $
Quotes you view appear here for quick access.

US Airways Group, Inc. Message Board

joesolomon333 2740 posts  |  Last Activity: 19 hours ago Member since: Oct 23, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • joesolomon333 by joesolomon333 Dec 16, 2012 9:20 PM Flag

    Thank you shorts for the extra $4.5 MILLION you have to give to the longs this week.

    Since Nov. 2011 your short interest has grown from 6MM shares to over 30 MILLION shares by 9/12. However, there are a few problems that were unforeseen:

    1. Fusilev has not only maintained market share but is growing and increasing market share. Z and Fotolyn are now in the house with B and A coming on.
    2. Daily trading volume has been cut by 50%.
    3. A share buyback was announced cutting the outstanding shares and increasing the EPS.
    4. A special dividend was announced which cost you $4.5 MM plus.
    5. The buyback will continue and additional special dividends may and likely will be announced at any time.
    6. The Q4 2012, Q1 2013 and 2013 Full Year Estimates were all INCREASED in the last 2 weeks. Almost $77 MM in Q4 and over $96 MM in Q1 2013. Both RECORDS for the 9th and 10th Straight Quarters.

    should have covered on 11/8/12 at $10.64. You could have gone long or short on that date. Should have gone long. Now, it is just a question of how much more you lose with no volume or float which allows you to even think about covering.

  • joesolomon333 by joesolomon333 Apr 27, 2014 2:43 AM Flag

    To see what idiot is going bash and short SPPI UP from $6 to $25. Enjoy the ride. Bought another 10,000 shares in the last 2 weeks. Thank you. See you at $25 when the real games begin when SPPI has $300 to $500 MM in revenue and should be a 6 multiple of revenues.

    If not, I will wait for the pipeline.

  • joesolomon333 by joesolomon333 May 9, 2013 8:46 AM Flag

    Average Analysts estimates were for:
    1. A (0.16) loss. BEAT by 0.11 with (0.05).
    2. $36.4 MM in revenue. BEAT by $2.3 MM with $38.7 MM; and
    3. Increased Cash by $20 MM to $163 MM! $163 MM in CASH!!!

    Analysts will have to revise their earnings estimates upwards for 2013 as they were only projecting a (0.28) loss for the entire year and already had the 2nd half being breakeven with earnings per share in 2014.

  • joesolomon333 by joesolomon333 Apr 5, 2013 10:36 PM Flag

    You never know.......... the real suit would be an upcoming Class Action suit by SPPI on behalf of the Company and its shareholders alleging and establishing the collusion between the Hedge Fund shortsellers and certain key executives of the primary Wholesale Buyers of Fusilev who willfully and intentionally colluded to massively short SPPI while continuing to overstock orders for their own financial gain. jmho of course.

  • Reply to

    This Board

    by asht5333 Jan 5, 2014 10:28 AM
    joesolomon333 joesolomon333 Jan 5, 2014 10:39 PM Flag

    "mature adult" - the antithesis of you.

  • joesolomon333 by joesolomon333 Dec 6, 2012 8:57 PM Flag

    Tutes own 50 MM out of 59 MM shares. Insiders own approximately 5 to 6 MM shares. Thus, retail is only at 3 to 4 MM shares. Almost 30 MM shares of the 59 MM loaned and sold short. Conclusions:

    1. Insiders are not loaning shares to shorts.
    2. Tutes are loaning shares to short sellers or shorting their own shares against the box.
    3. Therefore, the Tutes control and can make a short squeeze occur at any time they want.
    4. TUTES are LONG 50 MM shares. Even if the TUTES are shorting against the box with their own shares they STILL are 20 MM shares more LONG than short. Thus, they are WAY net Long.
    5. Retail is irrelevant and blowing in the wind. 3 to 4 MM shares do not "move the needle".
    6. Raj cannot control the Tutes. Not his fault. He is building a company and has done a wonderful job. The share buyback is really important and just exacerbates the short side problem.
    7. When the TUTES are convinced of the Fusilev situation, much less B and A, which is likely in the very near future, IMO SPPI's share price will more than double faster that dumperpooper can make it to the restroom.

  • Reply to

    Cash

    by joesolomon333 Apr 21, 2013 9:27 PM
    joesolomon333 joesolomon333 Apr 21, 2013 9:44 PM Flag

    Yes, it is just terrible that SPPI has a laughable $400 million market cap with $180 MM in annual revenues with 3 new FDA filings in the next 12 months for cancer drugs with a potential combined annual revenue run rate of more than a BILLION Dollars per year.

    $143 MM in cash as of 12/31/12. Plus, a 10 to 12 drug pipeline behind it including the two SP drugs for breast cancer etc.

    Is there a more undervalued BioTech today?......not even close.

  • Reply to

    Just Checking In

    by joesolomon333 Apr 27, 2014 2:43 AM
    joesolomon333 joesolomon333 Apr 27, 2014 2:53 AM Flag

    Before shortsht gets his/her panties in a wad:

    I mean $300 MM plus with Belinostat and Capistro-enabled Melphalan only. SP-2012 and on and on and on is the pipeline.

  • Reply to

    Just Checking In

    by joesolomon333 Apr 27, 2014 2:43 AM
    joesolomon333 joesolomon333 Apr 27, 2014 3:22 AM Flag

    Going to buy an additional 30,000 shares too so I hope it stays where it is a little longer.

  • Reply to

    Gunner

    by joesolomon333 Jan 5, 2013 11:46 PM
    joesolomon333 joesolomon333 Jan 6, 2013 8:07 PM Flag

    Since you cannot name ANY Biotech or other high growth stock whatsoever which is More Undervalued than SPPI based on its Current, Existing financial metrics,

    PE ratio , cash on hand, lack of dilution risks, share buyback, dividend, positive cash flow, EPS, insider ownership, extensive pipeline etc.:

    I will assume that you Agree and do not know any other such companies.

  • joesolomon333 by joesolomon333 Feb 8, 2013 9:32 PM Flag

    1. $200 plus MILLION in cash, cash equivalents, a/r;
    2. $300MM plus in revenue run rate;
    3. $1.50 EPS;
    4. Fusilev, Folotyn, Zevalin approved and revenue generating;
    5. Extensive and deep 10 to 15 additional drug pipeline;
    6. Vested Management with a CEO who has more stock and options than the retail shareholders in the aggregate;
    7. Two Top Amgen Execs now directing the marketing program;
    8. Short interest which needs to buy 50% of the entire float to cover their position;
    9. Institutional Ownership exceeding 80% of the total outstanding shares;
    10. Stock Buyback Plan in effect;
    11. Special Dividend in 12/12 with others possibly to come;
    12. Possible synergies between Fusilev, Folotyn and Belinostat;
    13. Possible acquisition of Topo which could add Worldwide rights to Belinostat;
    14. 8 CONSECUTIVE Record Quarters and 9 likely including 12/12;
    15. SPPI is already up over 15% in 2013;
    16. shorts have lost OVER $55 MILLION in portfolio value since 11/8 with special dividend;
    17. IMO, it will only get worse (much worse) for shorts in 2013;
    18. CREDIT SUISSE on Board now too;
    19. FUSILEV patent No. 6,500,829 extended from December 31, 2019 to March 7, 2022;
    20. Belinostat safety data released and subject to FDA filing in mid-2013;
    21. Renazorb had favorable Phase I results and is moving forward;
    22. MSN reports that various inquiries have been made by Big Pharma regarding buyout opportunities;
    23. FDA agreement for A with a new NDA filing and concurrent Phase III Trial for A;
    24. BLACKROCK acquires OVER an ADDITIONAL 1 MM More shares and now owns 8.57% of SPPI;
    25. Longs UP approximately $120 MM since 11/8/12 and shorts down $55 MILLION as of 2/1/13; and
    26. A friendly or hostile buyout could be announced at any day with SPPI's ridiculous 7 to 8 PE Ratio.

  • joesolomon333 by joesolomon333 Jan 13, 2013 11:31 PM Flag

    UP ALMOST 14% ALREADY in 2013:

    1. $200 plus MILLION in cash;
    2. $300MM plus in Revenue Run Rate;
    3. $1.50 EPS;
    4. Fusilev, Folotyn, Zevalin approved and revenue generating;
    5. Extensive pipeline with B and A up next;
    6. Vested Management with a CEO who has more stock and options than the retail shareholders in the aggregate;
    7. Two Top Amgen Execs now directing the marketing program;
    8. Short interest which needs to buy 60% of the entire float to cover their position;
    9. Institutional Ownership exceeding 87% of the total outstanding shares;
    10. Stock Buyback Plan in effect;
    11. Special Dividend in 12/12 with others possibly to come;
    12. Possible synergies between Fusilev and Folotyn;
    13. Possible acquisition of Topo which could add Worldwide rights to B;
    14. 9 CONSECUTIVE Record Quarters including 12/12.
    15. SPPI is already up ALMOST 14% in 2013;
    16. shorts have lost $65 MILLION in portfolio value since 11/8; and
    17. IMO, it will only get worse (much worse) for shorts in 2013.

  • joesolomon333 by joesolomon333 Apr 21, 2013 9:27 PM Flag

    $143 MILLION in cash and cash equivalents at 12/31/12. How much cash do you think SPPI has today? ALOT. How much will SPPI have at 12/31/13? ALOT.

    Plus, $180 million in annual revenues is very meaningful and Raj is a hawk on expenses. 3 pending FDA filings and Apaziquone is a complete 110% home run ball if approved. The release of study results for Apaziquone without blood in the bladder will be very indicative of the increased likelihood of FDA approval.

  • Reply to

    Watch it....:)

    by caveman.smile Jun 5, 2014 3:08 PM
    joesolomon333 joesolomon333 Jun 5, 2014 11:05 PM Flag

    Sorry, dk.
    I have no aliases. Don't need any.

    I also have bought an additional 12,000 shares since my last message. 18,000 more to go. Talk to you at $25 PPS plus.

    P.S. Let me know of another BioTech with $160MM in revenues, cash flow breakeven (which is non-GAAP if you do not know), has $120MM in cash) and has a Market Cap of $500MM or so.

    P.S.S. There are none. Most would be 5 to 9 times EXISTING revenues or 3 TIMES Max Pipeline, if greater.

    Run the numbers. Let's start with $1.4 BILLION today which is low $20's PPS .

    That is not even counting the PIPELINE which is off the chart. Let's chat in 2016. I intend to own 1% or more of the entire Company.

  • joesolomon333 by joesolomon333 Feb 12, 2014 11:28 PM Flag

    I am leaving the board as I feel that is the best for everyone. It is my decision and I wish each of you and SPPI the very best in Helping to Beat Cancer. I will continue to invest in and follow SPPI going forward as I do not believe there is a more undervalued biotech on Planet Earth.

    No need to respond as it does not matter.

    I reserve the right to come back and Congratulate everyone at $25 and again at every $5 PPS increment thereafter or so. Otherwise, I wish everyone the very best in life, health and happiness.

    Best regards always! Joe

  • joesolomon333 by joesolomon333 Dec 21, 2012 12:29 PM Flag

    Since November 8th, have now lost $35 MILLION in portfolio value including the special dividend payment of $4.5 MILLION to the LONGS.

    Sit tight and it will only get worse. Raj is taking af to the woodshed.

  • Reply to

    Shiny New Bags at the Annual Meeting

    by t.boone11 Jan 30, 2013 4:06 PM
    joesolomon333 joesolomon333 Jan 30, 2013 4:23 PM Flag

    Laughable. Here is reality:

    Jan 30, 2013 $11.93
    Jul 1, 2008 $1.33 adj. monthly close

    A 9 BAGGER in 4.5 years. Are you kidding?

    In the last 2.5 months, SPPI went UP from $10.64 to $11.93 PPS. The "bagholders" have made $85 MILLION and shorts have still lost $40 MILLION in portfolio value with the special dividend in the last 2 1/2 months alone.

  • joesolomon333 by joesolomon333 Jan 29, 2014 9:26 PM Flag

    I will let you leave the board and will never say a derogatory word about you again unless you post again on the board. Those are my terms and they are nonnegotiable.

    Otherwise, please reply to the following:
    1. How is the class action lawsuit going?
    2. How is that FDA so called "warning letter" going for you?
    3. How is the FDA investigation.

    Please provide authority and updates on all the above. P.S. You can't. You are lying.

    4. Please explain how you can possibly lose coming down to $6.92 and back UP to $8.53 PPS.

    Loser "coming and going". You can leave silently with your tail between your legs and I will not refer to you again. Once again, nonnegotiable.

  • joesolomon333 by joesolomon333 Dec 17, 2012 2:52 PM Flag

    The thumbsdown guys will all have fibromyalgia.

  • Reply to

    Pippo

    by pkarnett83 Jan 20, 2013 11:06 PM
    joesolomon333 joesolomon333 Jan 20, 2013 11:51 PM Flag

    Also, it may be helpful to consider the following:

    1. $200 plus MILLION in cash, cash equivalents, a/r;
    2. $300MM plus in revenue run rate;
    3. $1.50 EPS;
    4. Fusilev, Folotyn, Zevalin approved and revenue generating;
    5. Extensive pipeline with B and A up next;
    6. Vested Management with a CEO who has more stock and options than the retail shareholders in the aggregate;
    7. Two Top Amgen Execs now directing the marketing program;
    8. Short interest which needs to buy 60% of the entire float to cover their position;
    9. Institutional Ownership exceeding 87% of the total outstanding shares;
    10. Stock Buyback Plan in effect;
    11. Special Dividend in 12/12 with others possibly to come;
    12. Possible synergies between Fusilev and Folotyn;
    13. Possible acquisition of Topo which could add Worldwide rights to B;
    14. 8 CONSECUTIVE Record Quarters and 9 likely including 12/12;
    15. SPPI is already up over approx. 10% in 2013;
    16. shorts have lost OVER $45 MILLION in portfolio value since 11/8;
    17. IMO, it will only get worse (much worse) for shorts in 2013;
    18. Credit Suisse on Board now too; and
    19. FUSILEV patent No. 6,500,829 extended from December 31, 2019 to March 7, 2022.

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.